{
    "nctId": "NCT03055143",
    "briefTitle": "Study of Doxorubicin in Patients With Metastatic Breast Cancer/Advanced Ovarian Cancer",
    "officialTitle": "A Randomized, Open Label, Two Treatment, Two Period, Two Sequence, Single Dose, Crossover, Bioequivalence Study Of Doxorubicin Hydrochloride Liposome Injection, 2 mg/ml (50 mg/m2 Dose) of Sun Pharma Advanced Research Company Limited, India, And Caelyx\u00ae (Doxorubicin Hydrochloride) Liposome Injection, 2 mg/ml (50 mg/m2 Dose) of Schering-Plough, Belgium, in Patients With Metastatic Breast Cancer/Advanced Ovarian Cancer, Under Fed (Normal Breakfast) Conditions.",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer and Ovarian Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 29,
    "primaryOutcomeMeasure": "Maximum measured plasma concentration",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Availability of volunteer for the entire study period and willingness to adhere to protocol requirements as evidenced by written informed consent.\n2. Patients with metastatic breast cancer/advanced ovarian cancer having age within the range of between 18-55 years.\n3. Subjects who had no evidence of underlying disease\n4. Subjects who had signed written consent form\n\nExclusion Criteria:\n\n1. Females who were pregnant, breastfeeding, or are likely to become pregnant\n2. Subjects who had any medical condition (except metastatic breast cancer/advanced ovarian cancer) that could jeopardize their health or prejudice the results\n3. Subjects deemed uncooperative or noncompliant\n4. Smoking or consumption of any nicotine products",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT"
}